Retinoic Acid Enhanced Human Stem Cell Derived Blood Brain Barrier Model

Abstract

In one embodiment, the present invention is a method of creating a fully-human blood-brain barrier (BBB) model, comprising the steps of (a) obtaining a mixture of neural cells and brain microvascular endothelial cells (BMECs), wherein the neural cells and BMECs that comprise the mixture were produced from the differentiation of human pluripotent stem cells (hPSCs); (b) purifying BMECs from the mixture of neural cells and BMECs of step (a); and (c) co-culturing the purified BMECs with a cell type selected from the group consisting of pericytes, astrocytes and differentiated neural progenitor cells (NPCs), wherein a blood brain barrier model is created.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims benefit from U.S. Provisional Application 61 / 724,072, filed Nov. 8, 2012, which is incorporated herein by reference for all purposes.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH[0002]This invention was made with government support under NS052649 and AA020476 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND OF THE INVENTION[0003]The blood-brain barrier (BBB) comprises the brain microvascular endothelial cells (BMECs) which line brain capillaries and control trafficking between the bloodstream and neural tissue. These properties are tightly regulated by the surrounding microenvironment (termed the neurovascular unit) throughout BBB development and into adulthood. While this barrier is essential for preserving healthy brain activity, its dysfunction and deregulation is implicated in a number of neurological diseases (Zlokovic, 2008). Moreover, an intact BB...

AI Technical Summary

Benefits of technology

The present invention relates to a method of creating a fully-human blood-brain barrier (BBB) model using human pluripotent stem cells (hPSCs) to produce neural cells and brain microvascular endothelial cells (BMECs) that can be co-cultured with other cell types to create a BBB model. The method involves purifying the BMECs from the mixed neural cells and brain microvascular endothelial cells, and co-culturing them with specific cell types such as pericytes, astrocytes, or differentiated neural progenitor cells. The resulting BBB model has a high barrier function and is useful for studying the effects of various compounds on the BBB. The invention also provides a method for creating a retinoic acid (RA)-enhanced or RA-like compound-enhanced mammalian BBB model, which is useful for studying the effects of RA or RA-like compounds on the BBB.

Problems solved by technology

Unfortunately, studies involving BBB development and regulation can be difficult and time-consuming to conduct in vivo, and the ability to screen brain-penetrating therapeutics in vivo is restricted to a small number of researchers with technical expertise in such techniques.

Primary human BMECs typically possess moderate barrier properties but their availability and yield are both extremely low and thus this source of material cannot be scaled for large library screens.

Immortalized BMECs exhibit prodigious growth from a clonal population but often have poor barrier properties and are thus not optimal for screening therapeutics.

From a co-culture perspective, human neurons, astrocytes, and pericytes can also be difficult to obtain from primary tissue sources in large enough quantities for modeling purposes.

These collective issues have hindered the creation of a robust and readily accessible human BBB in vitro model for several decades (Deli, et al., 2005).

Images